ImmunityBio (IBRX) Short term Debt (2020 - 2023)

ImmunityBio (IBRX) has reported Short term Debt for 7 consecutive years, with $8.7 million the latest figure, recorded in Q3 2021.

• In Q3 2021, Short term Debt rose 541.37% year-over-year to $8.7 million; the TTM figure through Sep 2021 stood at $8.7 million (up 541.37% YoY), while the FY2020 annual figure was $14.8 million, up 2953.09% from the prior year.
• Short term Debt retreated to $8.7 million in Q3 2021 per IBRX's latest filing, from $16.7 million in the prior quarter.
• Across five years, Short term Debt topped out at $17.8 million in Q1 2021 and bottomed at $486000.0 in Q4 2019.
• Historically, Short term Debt has averaged $4.5 million across 5 years, with a median of $2.1 million in 2017.
• Annual changes were most pronounced in 2019 — Short term Debt tumbled 71.34% — and 2020, when it soared 2953.09%.
• ImmunityBio's Short term Debt stood at $2.4 million in 2017, then retreated by 28.23% to $1.7 million in 2018, then sank by 71.34% to $486000.0 in 2019, then jumped by 2953.09% to $14.8 million in 2020, then tumbled by 41.39% to $8.7 million in 2021.
• Business Quant data shows IBRX's Short term Debt at $8.7 million in Q3 2021, $16.7 million in Q2 2021, and $17.8 million in Q1 2021.